Summary of Origin Agritech Limited Conference Call Company Overview - **Company**: Origin Agritech Limited (NASDAQ: SEED) - **Industry**: Agricultural Biotechnology Key Points GMO Commercialization Developments - Origin Agritech received a Chinese GMO safety certificate for its transgenic maize, BBL2-2, developed in collaboration with the Biotechnology Institute of the Chinese Academy of Agricultural Sciences [7] - BBL2-2 maize is engineered with two insect-resistant genes (Cry1Ab and Cry3Bb) and one herbicide-tolerance gene (Cp4-epsps), providing protection against various pests [7] - The company expects several hybrids with these traits to enter GMO variety registration trials, with approvals anticipated in one to two years [7] Hybrid Performance - A new hybrid, OY728, is expected to be ready for commercial production in the next growing season, with accelerated seed production and sales planned over the next six to twelve months [8] - The latest commercial hybrid has shown significant advantages over traditional varieties, optimized for high-density planting [8] - Feedback from farmers indicates higher yields and better crop health compared to previous plantings [9] Gene Editing Business Progress - Origin Agritech has developed a high-yield corn inbred through gene editing, demonstrating over a 50% yield increase compared to non-edited inbreds [10] - The company has established the world's first induction line genetic transformation system, allowing rapid editing of maize inbred lines [11] - Gene-edited hybrids are in production trials, with commercial production expected soon [12] Revenue Generation and Product Launches - The corn variety Aoyu 728 is projected to cover over 1 million mu and generate approximately RMB 40 million (around $7 million) in revenue in the 2025 season [16] - The GMO hybrid corn seed variety Aoyu 64BF is expected to start small-scale seed production in winter 2024, with sales beginning in 2025 [16] - The planting area of NEC corn in Xinjiang has doubled, with projected profits between RMB 2 to 5 million (approximately $350,000 to $950,000) [23] Future Plans and Partnerships - The company is exploring various commercial pathways for its gene editing platform utilizing CRISPR technology [22] - Origin Agritech anticipates completing the national trials for Aoyu 64BF by the end of 2024, with approvals for additional hybrids expected in one to two years [19] - The drying facility for NEC corn in Xinjiang is in the final stages of construction, expected to be completed by September [24] Closing Remarks - The company emphasizes its commitment to enhancing shareholder value and achieving fair market value reflective of its potential [27]

Core Insights - Origin Agritech Ltd. has made significant advancements in GMO commercialization, hybrid performance, and gene editing technologies, positioning itself as a leader in agricultural biotechnology in China [1][2][6]. GMO Commercialization Developments - The company obtained China's GMO safety certificate for its transgenic maize, BBL2-2, which includes two insect-resistant genes and one herbicide-tolerance gene, making it the only maize variant in China resistant to coleopteran pests [2][3]. - Several hybrids incorporating these traits are entering GMO variety registration trials, with expectations for approval within 1-2 years, and one hybrid ready for commercial production in the next growing season [3]. Commercial Hybrid Performance - Origin Agritech's commercial hybrids have shown superior yield and resilience in field trials, optimized for high-density planting conditions [4]. - The new corn hybrid, OY728, has demonstrated excellent growth and yield potential, with production and sales expected to commence in 2025 [5]. Gene Editing Business Progress - The company has developed a high-yield corn inbred line through gene editing, achieving over a 50% yield increase compared to non-edited varieties [6]. - Cost reductions in hybrid seed production are anticipated due to enhanced genetic traits, and the establishment of a new genetic transformation system allows for rapid editing of maize inbred lines [7][8]. Revenue Generation and Future Plans - The corn variety Aoyu 728 is expected to generate approximately RMB 40 million (around $7 million) in revenue in the 2025 season, covering over 1 million mu [9][10]. - The GMO hybrid corn seed variety Aoyu 64BF is expected to start small-scale seed production this winter, with sales beginning next year [10][11]. Additional Developments - The planting area of NEC corn in Xinjiang has doubled, with projected profits between RMB 2 to 5 million (approximately $350,000 to $950,000) for this year's production [12]. - The construction of a corn drying and processing facility in Xinjiang is nearing completion, expected to be ready for the current harvest season [12].

Group 1 - Origin Agritech Ltd. will host a conference call on July 11, 2024, at 8:00 AM ET to engage with the investment community [1] - The presentation will be led by Dr. Gengchen Han, Chairman and CEO of Origin Agritech [1] - Investors can submit written questions via email by July 1, 2024 [1] Group 2 - Origin Agritech Limited, founded in 1997, is a leading agricultural technology company based in Beijing [3] - The company is known for its phytase corn, which was the first transgenic corn to receive a Bio-Safety Certificate from China's Ministry of Agriculture [3] - Origin has developed a strong biotechnology seed pipeline, including products with glyphosate tolerance and pest resistance traits [3]

Core Viewpoint - Origin Agritech Ltd. has made significant advancements in agricultural technology through the publication of a research article in Nature, focusing on gene editing to enhance maize yield and architecture [1][3]. Group 1: Research and Development - The company has successfully achieved fixed-point improvement of leaf angle in maize inbred lines using gene editing technology [1]. - Origin, in collaboration with China Agricultural University, has established the world's first efficient genetic transformation system for maize induction line Hi3, allowing rapid editing of major maize inbred lines [2]. - The induction line genetic transformation system developed by Origin offers broad application prospects for the commercial development of gene-edited corn, potentially revolutionizing maize cultivation [3][4]. Group 2: Commercialization and Market Potential - China is accelerating the commercialization of gene editing traits, with approvals for corn, soybeans, and wheat, and Origin's gene-editing corn is expected to be commercialized in 1-2 years [3]. - The market for the commercial breeding process of corn gene editing is estimated to exceed 10 billion yuan (approximately US$1.5 billion) [3]. - The company has obtained more than ten maize gene editing induction lines improved for various traits, including drought resistance and lodging resistance [4]. Group 3: Company Background - Origin Agritech Limited, founded in 1997, is a leading Chinese agricultural technology company known for its innovations in crop seed biotechnologies [5]. - The company has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and pest resistance traits [5].

BEIJING, May 15, 2024 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced its unaudited financial results for the six months ended March 31, 2024. The Company also provided updates on its key product developments and strategic initiatives. Financial Results Overview: Revenue Growth: Origin Agritech reported net revenues of RMB 92 million (US$13 million) for the first half of FY2024, marking a substantial increase ...

Exhibit 99.1 Origin Agritech Limited ("Origin" or the "Company"), an agriculture technology company in China, is filing its unaudited financial results for the first half of FY2024 ended March 31, 2024, prepared in accordance with United States generally accepted accounting principles. FINANCIAL RESULTS OVERVIEW The Company reported net revenue of RMB92.0 million (US$13.0 million) during the first half year of FY2024, compared to RMB66.1 million for the first half year of FY2023. Total operating expenses fo ...

Core Viewpoint - Origin Agritech Ltd. has received a GMO safety certificate for its transgenic maize, BBL2-2, marking a significant advancement in agricultural biotechnology and paving the way for its commercial launch [1][2]. Group 1: Product Development - BBL2-2 maize contains two insect-resistant genes (Cry1Ab and Cry3Bb) and one herbicide-tolerance gene (Cp4-epsps), making it resistant to various pests such as corn borer and armyworm [1]. - The certification of BBL2-2 confirms its compliance with stringent safety standards, which is expected to enhance agricultural productivity and sustainability [2]. - The company has also developed a high-yield corn inbred line through gene editing, showing a yield increase of over 50% compared to traditional corn in field trials [2]. Group 2: Company Vision and Leadership - Dr. Gengchen Han, Chairman and CEO of Origin Agritech, emphasized that the GMO safety certificate represents a transformative moment for the company and agricultural biotechnology in China [2]. - The company aims to lead the commercialization of BBL2-2, which promises significant improvements in crop resilience and yield [2]. Group 3: Company Background - Origin Agritech Limited, founded in 1997 and headquartered in Beijing, is recognized as a leading agricultural technology company in China, with a robust biotechnology seed pipeline [3]. - The company was the first to receive a Bio-Safety Certificate for transgenic corn from China's Ministry of Agriculture, showcasing its long-standing commitment to agricultural innovation [3].

Financial Performance - Origin Agritech reported an estimated half-year revenue of RMB 85-95 million, reflecting a growth of 30-40% compared to the same period in the previous fiscal year [1]. Product and Innovation Updates - Two new hybrids have completed three years of national trials and are expected to receive approval this summer, with commercial availability anticipated in 2025 [2]. - An additional 15 new hybrids have entered the national official registration trial, indicating the company's commitment to expanding its product portfolio [2]. - Four GMO hybrids are currently undergoing national trials, aimed at enhancing crop resilience and yield [2]. - The company has submitted a new application for a GMO bt/gt trait for biosafety certification, demonstrating its dedication to regulatory standards in agricultural biotechnology [3]. - The successful performance of the new NEC hybrid has led to plans for large-scale planting in Xinjiang, which is expected to enhance agricultural productivity and sustainability in the region [3]. Leadership Insights - Dr. Gengchen Han, Chairman and CEO, emphasized the company's leadership in agricultural innovation, strong financial performance, and progress in product development, aiming to address food security and agricultural sustainability challenges [4]. Company Background - Origin Agritech Limited, founded in 1997 and headquartered in Beijing, is recognized as a leading Chinese agricultural technology company, with a robust biotechnology seed pipeline that includes products with glyphosate tolerance and pest resistance traits [5].

Core Insights - Origin Agritech Ltd. has achieved a significant breakthrough in corn production technology with a new high-yield corn inbred line that increases productivity by over 50% compared to traditional corn varieties [1][2] - The company aims to integrate this gene-edited trait into its elite commercial corn line by the end of 2024, which is expected to enhance seed yield and reduce hybrid seed production costs [2] Company Overview - Origin Agritech Limited, founded in 1997 and headquartered in Beijing, is a leading agricultural technology company specializing in crop seed biotechnologies [3] - The company has a history of innovation, including the development of the first transgenic corn to receive a Bio-Safety Certificate from China's Ministry of Agriculture [3] Future Plans - The company plans to conduct field demonstrations and seed production trials in the summer of 2024 to showcase the performance of the new technology and its potential impact on the agriculture industry [2]

Core Viewpoint - Origin Agritech Ltd. has reported significant financial growth for the fiscal year 2023, driven by strong performance in hybrid corn seeds and advancements in biotechnology, positioning the company for a landmark year in 2024 [2][6]. Financial Performance - For the fiscal year ended September 30, 2023, revenue reached RMB 93.3 million (US$ 13 million), marking a 77.5% increase from RMB 52.6 million in the previous year [6]. - Net income attributable to Origin for the fiscal year was RMB 62.7 million (US$ 8.7 million), compared to RMB 2.35 million for the fiscal year ended September 30, 2022 [9]. - Total operating expenses for the fiscal year were RMB 32.2 million (US$ 4.5 million), up from RMB 29.1 million in fiscal year 2022 [7]. Operational Highlights - The company announced the selection of its GMO corn hybrid for a national demo plot and the establishment of a new 33,000-acre growing and processing facility in Xinjiang, which is expected to significantly increase revenue [4]. - A groundbreaking ceremony for a 100,000-ton corn drying base in Shihezi, Xinjiang, was held on July 12, 2023 [4]. - Development of a new gene-editing method was announced, reducing cross-procedure timing from 4-5 years to just one year [4]. Strategic Initiatives - The company is projecting over 30% sales growth in its hybrid corn seed segment and expects its Nutritionally Enhanced Corn (NEC) to contribute more than 50% to total revenue in 2024 [2]. - A RMB 2 million grant from the Xinjiang government was received to support the construction of a local Germplasm Bank and contract growing of NEC [5]. - The company finalized an agreement to convert approximately RMB 137.7 million in debt into equity, enhancing its financial health [5]. Research and Development - Research and development expenses remained stable at RMB 7.4 million (US$ 1 million) for fiscal year 2023, focusing on proprietary crop seeds and genetically modified products [8]. - The company is making advancements in gene editing technology, which is expected to enhance existing product lines and open new revenue streams [2]. Liquidity and Cash Flow - As of September 30, 2023, the company had approximately RMB 23.7 million (US$ 3.3 million) in cash and cash equivalents, an increase from RMB 17.7 million in the previous year [10]. - Net cash provided by operating activities was RMB 5.5 million (US$ 0.76 million) during fiscal year 2023, compared to RMB 3.3 million for the previous fiscal year [10].